12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord^®.

30th July, 2020 - Glycostem collaborates with LUMICKS to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population for cellular therapy.

19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment  of  multiple  solid  cancers, and Glycostem Therapeutics BV,  a  clinical  stage  and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered  into  a  de

12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan

11th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced the signing of a two agreements wit

9th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company today announced that Korean investor, E&F Healthcare Holdings and existing investor LUPUS Ventures B.V

September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced they have been awarded a €5 million loan from RVO’s Innovation Credit budget for clinical trials

25th June 2019 - Glycostem Therapeutics BV today announced they have received GMP license for Glycostem’s proprietary closed production system used to manufacture their lead product, oNKord^®, an off-the-shelf,allogeneic Natural Killer(NK) cell therapy.

28th March 2019 - Phio and Glycostem to Collaborate on Use of its sd-rxRNA^® platform and Glycostem's oNKord^® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment